ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0479

Prevalence and Severity of Hyperkalemia in Patients Referred to Nephrology Consultation: Epidemiologic Data from 1106 Mexican Patients at a National Reference Hospital

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Aviles, Mayra, Hospital General de Mexico Dr Eduardo Liceaga, Ciudad de Mexico, Ciudad de Mexico, Mexico
  • Perez-Navarro, L. Monserrat, Hospital General de Mexico Dr Eduardo Liceaga, Ciudad de Mexico, Ciudad de Mexico, Mexico
  • Escorza Valdivia, Samantha, Hospital General de Mexico Dr Eduardo Liceaga, Ciudad de Mexico, Ciudad de Mexico, Mexico
  • Benitez Renteria, Alberto Sigfrido, AstraZeneca, Ciudad de México, Ciudad de Mexico, Mexico
  • Valdez-Ortiz, Rafael, Hospital General de Mexico Dr Eduardo Liceaga, Ciudad de Mexico, Ciudad de Mexico, Mexico
Background

Hyperkalemia (HK, serum K > 5 mEq / L) is an electrolyte disorder that occurs frequently in patients with chronic kidney disease (CKD), heart failure. In CKD, the ability to excrete K+ is reduced, impairing quality of life and increasing morbidity and mortality

Methods

Cross-sectional retrolective, observational study. Records of adult patients who attended an outpatient Nephrology consultation in the period from February 2019 to February 2020 were included, with laboratory reports from the last 15 days prior to the date of the medical consultation. Descriptive statistics were performed, with a 95% CI and a p-value ≤0.05

Results

1106 patient records were included. 51% (563) were women. The mean age was 55.8 ± 15.6 years. 47% of the population had Diabetes mellitus and / or hypertension as their main comorbidity and 61% were overweight or obese. HK was identified in 29% of the study population. Figure 1 shows the frequency of HK by stage of CKD. 13% of the patients who entered the study were on renal replacement therapy, of which 54% had HK. 54% of the subjects with HK were diabetic, 56% hypertensive, 25% consumed ACE inhibitors and 13% consumed NSAIDs on a regular basis and 48% had proteinuria.

Conclusion

The presence of HK is a risk factor that increases the risk for cardiovascular complications and accelerates the progression to more advanced stages of CKD. It is important to intentionally search for this alteration in all stages of CKD and implement measures that help correct and mitigate its impact on patients with CKD

Funding

  • Commercial Support